Literature DB >> 29323441

A low muscle mass increases mortality in compensated cirrhotic patients with sepsis.

Cristina Lucidi1, Barbara Lattanzi1, Vincenza Di Gregorio1, Simone Incicco1, Daria D'Ambrosio1, Mario Venditti2, Oliviero Riggio1, Manuela Merli1.   

Abstract

BACKGROUND & AIMS: Severe infections and muscle wasting are both associated to poor outcome in cirrhosis. A possible synergic effect of these two entities in cirrhotic patients has not been previously investigated. We aimed at analysing if a low muscle mass may deteriorate the outcome of cirrhotic patients with sepsis.
METHODS: Consecutive cirrhotic patients hospitalized for sepsis were enrolled in the study. Patients were classified for the severity of liver impairment (Child-Pugh class) and for the presence of "low muscle mass" (mid-arm muscle circumference<5th percentile). The development of complication during hospitalization and survival was analysed.
RESULTS: There were 74 consecutive cirrhotics with sepsis. Forty-three of these patients showed low muscle mass. In patients with and without low muscle mass, severity of liver disease and characteristics of infections were similar. Mortality tended to be higher in patients with low muscle mass (47% vs 26%, P = .06). A multivariate analysis selected low muscle mass (P < .01, HR: 3.2, IC: 1.4-4.8) and Child-Pugh C (P < .01, HR: 3.3, 95% IC: 1.5-4.9) as independent predictors of in-hospital mortality. In Child-Pugh A-B patients, mortality was higher in patients with low muscle mass compared with those without (50% vs 16%; P = .01). The mortality rate and the incidence of complications in malnourished patients classified in Child-Pugh A-B were similar to those Child-Pugh C.
CONCLUSIONS: Low muscle mass worsen prognosis in cirrhotic patients with severe infections. This is particularly evident in patients with Child A-B cirrhosis in whom the coexistence of low muscle mass and sepsis caused a negative impact on mortality similar to that observable in all Child C patients with sepsis.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cirrhosis; decreased muscle function; infections; low muscle mass; sarcopenia; sepsis

Mesh:

Year:  2018        PMID: 29323441     DOI: 10.1111/liv.13691

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  20 in total

1.  Arm Skeletal Muscle Mass Is Associated With the Prognosis of Patients With Cirrhosis.

Authors:  Yoshihiro Shimono; Hirayuki Enomoto; Kyohei Kishino; Ei-Ichiro Moriwaki; Hiroki Nishikawa; Takashi Nishimura; Yoshinori Iwata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Current Medical Treatment for Alcohol-Associated Liver Disease.

Authors:  Gustavo Ayares; Francisco Idalsoaga; Luis A Díaz; Jorge Arnold; Juan P Arab
Journal:  J Clin Exp Hepatol       Date:  2022-02-12

3.  Myostatin deficiency not only prevents muscle wasting but also improves survival in septic mice.

Authors:  Masayuki Kobayashi; Shingo Kasamatsu; Shohei Shinozaki; Shingo Yasuhara; Masao Kaneki
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-07       Impact factor: 4.310

4.  Using l-Carnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis.

Authors:  Theodore S Jennaro; Michael A Puskarich; Marc R McCann; Christopher E Gillies; Manjunath P Pai; Alla Karnovsky; Charles R Evans; Alan E Jones; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2020-08-10       Impact factor: 4.705

Review 5.  Sarcopenia and frailty in decompensated cirrhosis.

Authors:  Puneeta Tandon; Aldo J Montano-Loza; Jennifer C Lai; Srinivasan Dasarathy; Manuela Merli
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

6.  Association of loss of muscle mass with mortality in liver cirrhosis without or before liver transplantation: A systematic review and meta-analysis.

Authors:  Ke-Vin Chang; Jin-De Chen; Wei-Ting Wu; Kuo-Chin Huang; Der-Sheng Han
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

7.  The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis.

Authors:  Rafael Paternostro; Katharina Lampichler; Constanze Bardach; Ulrika Asenbaum; Clara Landler; David Bauer; Mattias Mandorfer; Remy Schwarzer; Michael Trauner; Thomas Reiberger; Arnulf Ferlitsch
Journal:  Liver Int       Date:  2019-09-11       Impact factor: 5.828

Review 8.  Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver.

Authors:  Pankaj Puri; Radha K Dhiman; Sunil Taneja; Puneeta Tandon; Manuela Merli; Anil C Anand; Anil Arora; Subrat K Acharya; Jaya Benjamin; Yogesh K Chawla; Sunil Dadhich; Ajay Duseja; C E Eapan; Amit Goel; Naveen Kalra; Dharmesh Kapoor; Ashish Kumar; Kaushal Madan; Aabha Nagral; Gaurav Pandey; Padaki N Rao; Sanjiv Saigal; Neeraj Saraf; Vivek A Saraswat; Anoop Saraya; Shiv K Sarin; Praveen Sharma; Akash Shukla; Sandeep S Sidhu; Namrata Singh; Shivaram P Singh; Anshu Srivastava; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2020-10-01

Review 9.  Muscle Loss in Chronic Liver Diseases: The Example of Nonalcoholic Liver Disease.

Authors:  Jean-Pascal De Bandt; Prasanthi Jegatheesan; Naouel Tennoune-El-Hafaia
Journal:  Nutrients       Date:  2018-09-01       Impact factor: 5.717

10.  The Effect of 12 Weeks of β-Hydroxy-β-Methyl-Butyrate Supplementation after Liver Transplantation: A Pilot Randomized Controlled Study.

Authors:  Barbara Lattanzi; Michela Giusto; Carlina Albanese; Gianluca Mennini; Daria D'Ambrosio; Alessio Farcomeni; Stefano Ginanni Corradini; Massimo Rossi; Manuela Merli
Journal:  Nutrients       Date:  2019-09-19       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.